This article was originally published here
Cancer Med. October 20, 2021. doi: 10.1002 / cam4.3981. Online ahead of print.
OBJECTIVE: A growing body of evidence has shown an indispensable role for N6 -methyladenosine (m6 A) in human diseases, but variations in copy number (CNV) of m6 A regulatory gene in bladder cancer (BLCA) remains largely unknown.
METHODS: We studied CNVs on all known m6 Regulatory genes using the Cancer Genome Atlas (TCGA) database. The association between CNV events and clinicopathologic as well as molecular characteristics of BLCA patients was explored. Gene set enrichment analysis (GSEA) was performed to reveal related cellular processes. Association between m6 A regulatory gene and immune infiltrates were analyzed by The Tumor Immune Estimation Resource (TIMER) database.
RESULTS: CNV events of m6 Regulatory genes have been observed frequently in BLCA. CNVs of METTL3, METTL14 and METTL16 were correlated with the molecular characteristics of BLCA patients, including the TP53 mutation. CNVs of METTL3 associated with the overall survival (OS) of BLCA patients. METTL3 was also associated with several cellular cancer-related processes, including mitotic spindle assembly, the G2 / M checkpoint, and the E2F target signaling pathway. In addition, the CNVs of m6 Regulatory genes have been correlated with specific types of immune infiltrates.
CONCLUSIONS: There are significant correlations between m6 A regulatory gene with CNV and clinicopathological features. METTL3 along with CNVs have been associated with immune infiltrates and performed as a prognostic marker in BLCA.